An asymmetric cascade reaction between β-keto acylpyrazoles and o-quinone methides in a formal [4 + 2] fashion to access potentially pharmacological active trans-3,4-dihydrocoumarins has been achieved efficiently by using a quinine-based chiral squaramide as the catalyst. The desired products were obtained in high yields with excellent diastereo- and enantioselectivities (up to 96% yield, >19/1 dr and 96% ee) under mild reaction conditions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.joc.8b00234 | DOI Listing |
J Org Chem
September 2024
Department of Chemistry, University of San Francisco, San Francisco, California 94117, United States.
Substituted 5-hydroxy γ-pyrones have shown promise as covalent inhibitor leads against cysteine proteases and transcription factors, but their hydrolytic instability has hindered optimization efforts. Previous mechanistic proposals have suggested that these molecules function as Michael acceptor prodrugs, releasing a leaving group to generate an -quinone methide-like structure. Addition to this electrophile of either water or an active site cysteine was purported to lead to inhibitor hydrolysis or enzyme inhibition, respectively.
View Article and Find Full Text PDFOrg Lett
June 2024
Henan University of Chinese Medicine, Zhengzhou 450046, China.
The hybrid nature of Pd(I)-alkyl radical species has enabled a wide array of radical-based transformations. However, in this transformation, the secondary Pd(I)-alkyl radical species are prone to recombining into Pd(II)-alkyl species to give Heck-type products via β-H loss. Herein, we report a visible-light-induced, three-component Pd-catalyzed 1,2-aminoalkylation of alkenes with readily available alkyl halides and amines to construct C-C and C-N bonds simultaneously.
View Article and Find Full Text PDFACS Appl Bio Mater
June 2024
Department of Chemistry, Pohang University of Science and Technology, Pohang 37673, South Korea.
Mitigating the adverse effects of anticancer agents requires innovative prodrug engineering. In this study, we showcase the potential of our -quinone methide-based trigger-release-conjugation platform as a versatile tool for constructing advanced prodrug systems. Using this platform, we achieved the light-triggered release of an anticancer drug mechlorethamine, targeting mitochondrial DNA.
View Article and Find Full Text PDFOrg Lett
December 2023
Institute of Green Chemistry and Molecular Engineering, School of Chemistry, Sun Yat-Sen University, Guangzhou 510275, China.
A visible light-promoted radical (3+3) annulation of vinyldiazo compounds and bromodifluoromethyl alkynyl ketones for the construction of -difluoro-masked -quinone methides (-QMs) is described. The reactivity of this new type of -QM precursor is demonstrated by its (4+1) cycloaddition with sulfur ylides, affording monofluorinated aromatic benzofurans by the elimination of HBr without external oxidants.
View Article and Find Full Text PDFJ Org Chem
November 2023
Facultad de Química, Universidad Nacional Autónoma de México, CDMX, 04510 Mexico City, Mexico.
Contrary to our previous report in which a Pd-catalyzed three-component reaction of a steroid alkynol, trimethyl orthoformate, and salicylaldehyde exclusively produced chroman ketals, the same reaction employing 2,5-dihydroxysalicylaldehyde led to a mixture of a chroman ketal and a spiroketal. Provided that both courses of the reaction imply a 4 + 2 inverse demand cycloaddition between an -quinone methide and an enol ether, density functional theory calculations revealed that the chroman ketal/spiroketal selectivity is governed by both, the rate of the formation of the -quinone methide and the isomerization of the initially produced exocyclic enol ether─that led to the spiroketal─to its endocyclic partner that produces the chroman ketal. Remarkably, Lewis catalysis is central to the observed reactivity, and the availability of plausible catalytic species controls the overall chemoselectivity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!